Published in Expert Opin Ther Targets on February 01, 2003
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2006) 2.75
TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 2.68
Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol (2004) 1.53
Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res (2001) 1.47
BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol (2004) 1.29
Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem (2002) 1.29
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol (2005) 1.28
The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev (2003) 1.26
Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol (2002) 1.23
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry (2005) 1.23
Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem (2003) 1.17
Dual role for TWEAK in angiogenic regulation. J Cell Sci (2002) 1.16
Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol (2010) 1.13
A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation (2009) 1.12
Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma. J Clin Invest (2010) 1.06
Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol (2002) 1.06
Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs (2011) 1.04
Transition to adult services among behaviorally infected adolescents with HIV--a qualitative study. J Pediatr Psychol (2009) 1.02
Tweak induces mammary epithelial branching morphogenesis. Oncogene (2005) 1.02
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Posttraumatic stress and trauma history in adolescents and young adults with HIV. AIDS Patient Care STDS (2007) 1.00
The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol (2004) 0.93
Description of a novel pediatric emergency department-based HIV screening program for adolescents. AIDS Patient Care STDS (2008) 0.90
Murine peptidoglycan recognition proteins PglyrpIalpha and PglyrpIbeta are encoded in the epidermal differentiation complex and are expressed in epidermal and hematopoietic tissues. Genomics (2004) 0.89
Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One (2011) 0.88
The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun (2005) 0.84
Development and validation of a noninvasive method to estimate cardiac output using cuff sphygmomanometry. Clin Cardiol (2007) 0.81
CD8alphabeta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I. J Biol Chem (2006) 0.81
EC144 is a potent inhibitor of the heat shock protein 90. J Med Chem (2012) 0.81
CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes. Infect Immun (2002) 0.81
Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol Immunol (2002) 0.77
An active CD8alpha/pMHCI interaction is required for CD8 single positive thymocyte differentiation. Eur J Immunol (2010) 0.75